Biogen made headlines in late October when they announced their intention to restart clinical studies of aducanumab after being shut down seven months prior. Since then, scientists, analysts and advocacy groups have been weighing in on whether an approval is in sight. Phase III studies were halted in March based on a futility study predicting […]